NEXBIOME

Direct Investment

Early BioTech - Unicellular Delivery Mechanism

MEVs (microalgal extracellular vesicles) are the cornerstone of the AGS technology platform, forming the basis for our therapeutic, vaccine, and gene therapy products.

MEVs are naturally occurring, nanosized lipid-bilayer particles known as extracellular vesicles, derived from unicellular green microalgae like Chlorella. Imagine your body welcomes medicine instead of rejects it, because the delivery mechanism is made of chlorella, an organic material that is healing for the body.

AGS Website

Raising $6M Pre-series A

EMAIL TO INVEST or MEET

AGS Materials (Copy) (Copy) (Copy) (Copy)

AGS Materials (Copy) (Copy) (Copy) (Copy)

AGS Materials (Copy) (Copy) (Copy) (Copy)

AGS Materials (Copy) (Copy) (Copy) (Copy)

AGS

AGS Therapeutics is an early-stage biotechnology company pioneering a novel drug delivery platform using Microalgae Extracellular Vesicles (MEVs) and developing an internal R&D pipeline.

AGS mechanisms move through the body unlike synthetic, animal or human made delivery mechanisms.